



PATENT

Attorney Docket No. 056291-5202

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Alan BARGE**Application No.: **10/530,566**International Appln. Filing Date: **October 6, 2003**For: **COMBINATION THERAPY WITH
GEMCITABINE AND ZD6126**Group Art Unit: *Unassigned*Examiner: *Unassigned*

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**Citation of Related U.S. Patent Applications**

The Examiner's attention is directed to the following related co-pending U.S. patent applications:

Inventor	U.S. Serial No. Filing Date	U.S. Patent No. Issue Date	PCT Publication No. PCT Publication Date
	09/890,989		WO 00/48591 August 24, 2000
	10/129,336		WO 01/32651 May 10, 2001
Curwen et al.	10/240,413 October 1, 2002		WO 01/74360 October 11, 2001
Davis et al.	10/240,213 April 4, 2003		WO 01/74368 October 11, 2001

A copy of the specification and claims for each application, in the form of the published PCT application from which such application was filed is being filed herewith.

PLEASE DO NOT PRINT the above information on the patent resulting from the subject application.

Consideration of each listed application is earnestly solicited since unpublished patent applications are contemplated as IDS material; see the exception in Rule 98(a)(2)(iii) and note the penultimate sentence of MPEP 609.

Further, in keeping with MPEP 609, Subsec. C(2), 2nd para., line 10 to end of the paragraph (especially note lines 18-25) PLEASE RETURN A COPY OF THIS LETTER with the Examiner's initials adjacent each above listing so that applicant will know that each listed application has been considered as required by PTO policy.

Citation of Documents

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants petition the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Supplemental Information Disclosure Statement.


With the exception of U.S. Patents and published U.S. Applications, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that the listed documents constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP



Date: October 21, 2005
Morgan Lewis & Bockius LLP
Customer No. 09629
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000

By: _____

Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

PTO Form 1449

Attorney Docket
056291-5202

Application No. 10/530,566

Applicants: Alan BARGE

PAGE 1 of 1

I. A. Filing Date: October 6, 2003

Group Art Unit: *Unassigned***U.S. PATENT DOCUMENTS**

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
1.	US 6,423,753	July 23, 2002	Dougherty	514	719	January 5, 2000
2.	US 20030055024	March 20, 2003	Davis	514	114	September 26, 2002
3.	US 20030166617	September 4, 2003	Davis et al.	514	114	April 4, 2003

FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Class	Sub-Class	Translation
4. WO 99/02166	January 21, 1999	WIPO			
5. WO 00/48591	August 24, 2000	WIPO			
6. WO 01/32651	May 10, 2001	WIPO			
7. WO 01/74360	October 11, 2001	WIPO			
8. WO 01/74368	October 11, 2001	WIPO			
9. WO 02/56692	July 25, 2002	WIPO			
10. WO 03/088971	October 30, 2003	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

11.	Blakey et al. (2002) "Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models" Clin. Cancer Res. 8: 1974-1983
12.	Bruns et al. (2002) "Vascular-targeting activity of ZD6126 against primary pancreatic tumour growth and lymph node metastasis following orthotopic tumour cell injection in a nude mouse model" 14th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Abstract 118
13.	Chaplin et al. (2002) "The development of combretastatin A4 phosphate as a vascular targeting agent" Int J Radiat Oncol Biol Phys. 54(5): 1491-1496
14.	Davis et al. (2002) "ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature" Cancer Res. 62(24): 7247-7253
15.	Grosios et al. (2000) "Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma" Anticancer Res. 20: 229-233
16.	Horsman et al. (2000) "Combretastatins novel vascular targeting drugs for improving anti-cancer therapy" Advances in Experimental Medical Biology 476: 311-323
17.	Li et al. (2002) "Preclinical evaluation of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma" Acta Oncol. 41(1):91-97
18.	Siemann et al. (2002) "Enhancement of radiation therapy by the novel vascular targeting agent ZD6126" Int J Radiat Oncol Biol Phys. 53(1): 164-171
19.	Siemann et al. (2002) "Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy" Int J Cancer 99(1): 1-6
20.	Thorpe et al. (2003) "The First International Conference on Vascular Targeting: Meeting Overview" Cancer Res 63: 1144-1147

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.